Karuna Therapeutics, Inc. (KRTX)
| Market Cap | 2.67B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.32M |
| Shares Out | 26.66M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $99.42 |
| Previous Close | $102.80 |
| Change ($) | -3.38 |
| Change (%) | -3.29% |
| Day's Open | 104.31 |
| Day's Range | 97.64 - 105.81 |
| Day's Volume | 194,624 |
| 52-Week Range | 60.41 - 117.21 |
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc.
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...
Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.
As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).
COVID-19 and initial public offerings don’t go well together.
The volatile biotech has been up and down since its massive gain back in November.
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.
An index that tracks initial public offerings has outperformed the S&P 500 in what could be a historic year for stocks.
Is the stock a buy now that the price has dropped?
These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?
In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.
4 Biotech Neurology Stocks, As Biotechs March On
Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock.
As of late, it has definitely been a great time to be an investor Karuna Therapeutics
Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study
Karuna Therapeutics: Fundraising Makes For Buying Opportunity
"We're cautiously optimistic given the robustness of the clinical data that we reported this week," Karuna Therapeutics CEO Dr. Steve Paul says.
Karuna Therapeutics soars on potentially 'game changing' new schizophrenia drug
Karuna CEO Dr.
History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.
The pharma company announced the pricing of a public stock offering.
Positive clinical trial results recently sent this stock soaring, but can it climb further?
Karuna Therapeutics Inc. (NASDAQ: KRTX) shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment.
Shares of Karuna Therapeutics have septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test.
The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.
Some surprising events lifted these stocks.
When investors see a stock rise by close to 100%, they probably just assume it’s a corporate buyout.
Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring. The post Karuna Therapeutics News: KRTX Stock Skyrockets 415%...
The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate.
Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial ...
Shares of the thinly traded, small-cap biotech Karuna Therapeutics Inc (NASDAQ: KRTX) were moving higher Monday on a positive clinical trial readout.
Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream
About KRTX
Karuna Therapeutics, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of... [Read more...]
| Industry Biotechnology | IPO Date Jun 28, 2019 |
| CEO Dr. Steven M. Paul M.D. | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol KRTX |
Analyst Forecasts
According to 12 analysts, the average rating for KRTX stock is "Strong Buy." The 12-month stock price forecast is 130.82, which is an increase of 31.58% from the latest price.